A Study of Pemetrexed and Carboplatin/Cisplatin or Gemcitabine and Carboplatin/Cisplatin With or Without IMC-1121B in Participants Previously Untreated With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC)

Inclusion Criteria:

- Confirmed NSCLC

- Stage IV disease at the time of study entry

- Measurable disease at the time of study entry

- Resolution to Grade ≤ 1 Adverse Events, of all clinically significant toxic effects of
prior chemotherapy, surgery, radiotherapy, or hormonal therapy (except alopecia)

- Adequate hematologic function, hepatic function, renal function and coagulation
function

- If sexually active, must be post-menopausal, surgically sterile, or using effective
contraception; and agrees to use adequate contraception during the study period and
for up to 6 months after the last dose of study medication

- Female participants of childbearing potential must have a negative serum pregnancy
test

Exclusion Criteria:

- Has cirrhosis at a level of Child-Pugh B (or worse), or cirrhosis and a history of
hepatic encephalopathy, or ascites resulting from cirrhosis and requiring ongoing
treatment with diuretics and/or paracentesis

- Tumor wholly or partially contains small cell lung cancer

- Untreated central nervous system (CNS) metastases, eligible if they are clinically
stable with regard to neurologic function, off all steroids after cranial irradiation
at least 2 weeks prior or after surgical resection performed at least 4 weeks prior to
randomization

- Concurrent active malignancy other than adequately treated basal cell carcinoma of the
skin or pre-invasive carcinoma of the cervix. A participant with previous history of
malignancy other than NSCLC is eligible, provided that he/she has been free of disease
for ≥ 3 years

- Received prior therapy with monoclonal antibodies, signal transduction inhibitors, or
any therapies targeting the vascular endothelial growth factor (VEGF) or vascular
endothelial growth factor receptor (VEGFR)

- Receiving concurrent treatment with other anticancer therapy

- Has received previous chemotherapy for Stage IV NSCLC (participants who have received
adjuvant chemotherapy are eligible if the last administration of the prior adjuvant
regimen occurred at least 6 months prior to randomization)

- Has radiologically documented evidence of major blood vessel invasion or encasement by
cancer

- Has undergone chest irradiation within 12 weeks prior to randomization (except
palliative irradiation of bone lesions)

- Ongoing or active infection

- History of significant neurological or psychiatric disorders

- Experienced clinically relevant coronary artery disease, myocardial infarction within
6 months prior to randomization, uncontrolled congestive heart failure, or symptomatic
poorly controlled arrhythmia

- Poorly-controlled hypertension

- Experienced any serious Grade 3-4 gastrointestinal bleeding within 3 months prior to
study entry

- Receiving chronic daily treatment with aspirin (> 325 mg/day) or other known
inhibitors of platelet function

- Serious nonhealing wound, ulcer, or bone fracture within 28 days prior to
randomization

- Major surgery within 28 days prior the first dose of study medication, or subcutaneous
venous access device placement within 7 days prior to randomization

- Elective or a planned major surgery

- Pregnant or lactating

- Any other serious uncontrolled medical disorders or psychological conditions

- Allergy / history of hypersensitivity reaction to any of the treatment components

- History of drug abuse